The Price of Remission

Published: Thursday, May 8, 2025 at 9:00 am

The Price of a Second Chance: How a Life-Saving Cancer Drug Became a Financial Burden

This article delves into the complex world of prescription drug pricing, focusing on Revlimid, a life-extending medication for multiple myeloma, a blood cancer. The author, a journalist diagnosed with the disease, shares their personal experience navigating the high cost of treatment. The story begins with the author's diagnosis and the shocking price tag of Revlimid, a drug derived from thalidomide, a medication with a dark past.

The article traces the drug's journey, from its initial development by Celgene, a company that acquired the rights to thalidomide, to its current status as a blockbuster drug. It highlights the pivotal role of Dr. Bart Barlogie and Beth Wolmer, whose relentless pursuit of treatment for her husband, Ira, led to the discovery of thalidomide's potential in fighting cancer. The article details how Celgene, through strategic patenting, aggressive pricing strategies, and lobbying efforts, maintained its monopoly on Revlimid, driving up its cost to exorbitant levels. The author reveals how the company repeatedly raised the price, even as the cost to manufacture the drug remained minimal.

The article also examines the impact of these high prices on patients, forcing some to make difficult choices, including rationing medication or going into debt. It explores the role of generic competition, the tactics used by Celgene to delay the entry of generics, and the eventual settlement agreements that allowed them to maintain their market dominance. The author's personal experience underscores the financial and emotional toll of cancer treatment, even with access to life-saving medication.

BNN's Perspective: This article paints a stark picture of the pharmaceutical industry's pricing practices. While the development of life-saving drugs is crucial, the exorbitant cost of Revlimid raises serious questions about the balance between innovation and patient access. It's a complex issue, and while companies need to recoup their investment, the current system seems to prioritize profits over the well-being of those who need these medications most. Finding a middle ground that allows for both innovation and affordability is essential.

Keywords: Revlimid, multiple myeloma, cancer, thalidomide, Celgene, drug pricing, generic drugs, Beth Wolmer, Dr. Bart Barlogie, pharmaceutical industry, healthcare costs, patient access, Bristol Myers Squibb, FDA, patents, drug development, high prices, cost of treatment, generic competition, healthcare, prescription drugs, cancer treatment.

Full Story